Acticor Biotech Archives

Home Acticor Biotech

Latest Posts

Best in Biotech 8 Jun 2023

Six companies that have made their name in the cardiovascular space

Cardiovascular disease is a general term used to describe a disease that affects the heart and blood vessels. According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, with statistics from 2019 stating that an estimated 17.9 million people died from some type of cardiovascular disease, making up 32% […]

June 8, 2023 - 7 minutesmins - By Willow Shah-Neville

cardiology cardiovascular disease heart attack

News and Trends 23 Nov 2022

Trial to start for new heart attack drug

A potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K. With the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place in two acute care hospitals in the U.K.: the Queen Elizabeth Hospital, Birmingham […]

November 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 26 Sep 2022

Acticor Biotech enrolls first U.S. patient in study for people with acute ischemic stroke

The first U.S. patient was enrolled in a study evaluating glenzocimab in those with acute ischemic stroke. Acticor Biotech, a clinical stage biotech company, made the announcement today (September 26). The patient was enrolled at the CHI Memorial Stroke and Neuroscience Center, Chattanooga, Tennessee, by neurologist, Ruchir Shah. Significant potential He said: “I am very […]

September 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Jul 2022

Stroke drug given priority medicine status by European Medicines Agency

A biotech company developing drugs for cardiovascular emergencies, specifically strokes, has received priority medicines status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab. Paris-based Acticor Biotech made the announcement yesterday (July 21) and the prime status allows reinforcement of support for the development of drugs that target an unmet medical need. It […]

July 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 30 Jun 2022

Acticor Biotech gets patent for cardiovascular emergency treatment product

French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in Europe until 2036. The grant in Europe complements the ones already obtained in November 2020 in the U.S. and in November 2021 in Singapore, both […]

June 30, 2022 - 2 minutesmins - By Jim Cornall

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us